Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
about
Fluoxetine for adult overweight or obese peopleTesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese ratTrace amine-associated receptor 1 as a monoaminergic modulator in brainPharmacological targeting of the serotonergic system for the treatment of obesityAnorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbensQuantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disordersThe serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's diseaseStructure-activity relationships of constrained phenylethylamine ligands for the serotonin 5-HT2 receptorsA multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinitiesCombinations of drugs in the Treatment of Obesity.Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.Impact of RNA editing on functions of the serotonin 2C receptor in vivoSystemic modulation of serotonergic synapses via reuptake blockade or 5HT1A receptor antagonism does not alter perithreshold taste sensitivity in rats.Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment.Pharmacologic treatment options for obesity: what is old is new again.Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.Pharmacological treatment of obesity in children and adolescents: present and futureAMPK as Target for Intervention in Childhood and Adolescent ObesityLorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndromeFluoxetine prevents 8-OH-DPAT-induced hyperphagia in Fischer inbred ratsThe use of serotonergic drugs to treat obesity--is there any hope?Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model.Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboonsThe selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats.Treatment options for obesity and potential therapies on the horizonProfiling hepatic microRNAs in zebrafish: fluoxetine exposure mimics a fasting response that targets AMP-activated protein kinase (AMPK)A New Strategy Using Rikkunshito to Treat Anorexia and Gastrointestinal DysfunctionThe 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse controlDynamic 5-HT2C receptor editing in a mouse model of obesity.Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival.Associations between central nervous system serotonin, fasting glucose, and hostility in African American females.Fluoxetine Decreases the Proliferation and Adipogenic Differentiation of Human Adipose-Derived Stem Cells.TPH2 G/T polymorphism is associated with hyperphagia, IQ, and internalizing problems in Prader-Willi syndrome.5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamenCerebral markers of the serotonergic system in rat models of obesity and after Roux-en-Y gastric bypassThe selective serotonin reuptake inhibitor paroxetine decreases breakpoint of rats engaging in a progressive ratio licking task for sucrose and quinine solutions.The behavioral pharmacology of anorexigenic drugs in nonhuman primates: 30 years of progress.Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice.
P2860
Q24188314-DA50F643-AEF4-4756-8267-3963057428F6Q24602893-32C56C08-F5F7-4E05-A6AF-9859A2BF84A3Q24650242-7B5C255F-31A7-405E-8E94-CA7C253C418FQ24658013-9F10EFAD-B842-44A3-A62A-0CDDE7B7B132Q24674037-54CED7BE-990A-4949-A9DB-7DE0C6109263Q27014825-C85B3266-8C77-4D94-BE10-7F7B486CFDE6Q28251394-22FFA85E-F84A-4AD1-82D9-E89318AB3F0BQ28534941-AA9D9ED6-827E-4EFF-A1F7-86313F087B73Q30657759-83E37167-45F4-44C9-95F2-D2169E1C3BC2Q33664063-1327D9CB-C0FF-430E-B6A8-1E80C527AE1BQ33688119-F948DE56-B3F4-41B7-A7A0-A2FF1A153ED8Q33806232-F8141843-8B21-4E68-99E6-3053CF4B94FCQ34048296-FA1E8260-F975-41D4-AE96-7D703CCCFA8CQ34279909-238D9F67-1E40-4CB3-A79B-A4B31A083C57Q34341681-D4AA2883-836C-48DD-9978-C826F0DF8FB7Q34407191-C7223265-AF35-4EF7-911B-024C363D256DQ34442880-BA4133E9-1663-4A5F-AFFD-E7D5C8692255Q34557477-EB13275A-5895-4AB8-A5E6-E5E8F3DEA6E1Q34659424-1E188EA0-E850-4D2C-BA4E-50977E64B86FQ34661571-2B4BC4EA-8C09-4F0A-BAB8-89CDF865347AQ34669261-81E49A43-43D5-4ADA-B0F3-A342931D3450Q34672013-DA31D82A-7F98-4444-BA2E-5C0F4879DDFDQ34712327-2CA823A4-6BD4-4781-BD0D-0746B0710687Q34971199-4029185B-3813-4188-B3CC-90DF7A3C0D26Q35023998-E65E3CCB-D21B-419A-AC6C-20811CD43CCCQ35033624-2F20ED8B-8736-4904-9786-66D853F6D5B8Q35111291-EAE5BF56-D0AE-4B46-99F0-35FF6D5BC772Q35154001-DCA076E9-DBB8-4CD4-AD78-85B2303FE170Q35612563-985357CE-20B5-4B72-AEB8-A135267E45E8Q35837700-EA424AA1-B849-47BE-9068-B3D008556BB9Q35842417-D51C42DA-209C-46BF-B94A-4032E57B9D06Q35844223-AF35E916-F9F5-4798-9B78-C74FC76EB19FQ35845425-DCC14D60-B65C-445B-A8DA-2C3BD741663CQ35902690-79EB11FF-4009-4A43-82BB-A59942854178Q35963550-30C30D58-B665-4ED1-9034-A4F40A532962Q36334398-E05AE675-6E82-4902-B3DC-3AE7B4CD9570Q36583824-A3302F6B-EAF2-4EDF-9CB5-443BE23176E2Q36602077-9FFEABE8-B63F-467C-9DDA-2B9649D12462Q36922499-430A5C88-D1A2-4111-85A6-68BCA47F4539Q37015833-DC7DA0E1-96D0-4FEF-ABE2-012FF9D77AA5
P2860
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@ast
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@en
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@nl
type
label
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@ast
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@en
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@nl
prefLabel
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@ast
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@en
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@nl
P2093
P1433
P1476
Serotonergic drugs : effects on appetite expression and use for the treatment of obesity
@en
P2093
Emma J Boyland
Jason C G Halford
Joanne A Harrold
P356
10.2165/00003495-200767010-00004
P407
P577
2007-01-01T00:00:00Z
P6179
1051517934